Details:
Takeda will have access to Genevant’s innovative LNP technology to develop nucleic acid therapeutics directed to specified targets in historically inaccessible hepatic stellate cells to treat liver fibrosis.
Lead Product(s): LNP based nucleic acid therapeutics
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2021